TAN News 40.13 06/05/2014 05:29:20 Solar ETF Guggenheim (TAN

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Solar ETF Guggenheim (TAN) 40.13 $TAN

Solar Energy Stocks Get Second Wind Following 2012 Collapse
at The Street - Tue May 27, 8:41AM CDT
The solar energy sector has been making some big noise for investors since bottoming out in 2012.

Solar ETFs Shine on Trina Solar Earnings Beat - ETF News And Commentary
Sweta Killa - ZACKS - Thu May 22, 12:00PM CDT
Trina Solar solid beat has spread strong optimism in the broad solar industry, pushing these ETFs higher.

Will Solar ETFs be Powered by Earnings Beat? - ETF News And Commentary
Sweta Killa - ZACKS - Thu May 08, 2:00PM CDT
Will earnings beat from solar biggies could save these ETFs?

Knowing ETF Firms' Traits Can Help You Sort Field
at Investor's Business Daily - Thu Apr 17, 5:15PM CDT
In the world of ETFs, there are large ETF issuers and there are tiny ones. Aside from looking at the asset size and the availability of a particular ETF that fits an investor's strategy, one needs to consider other differentiating factors among ETF...

Claymore/MAC Global Solar Energy Index ETF Shares Down 11.5% Since SmarTrend's Sell Call (TAN)
Comtex SmarTrend(R) - Mon Apr 14, 9:27AM CDT
SmarTrend identified a Downtrend for Claymore/MAC Global Solar Energy Index ETF (NYSE:TAN) on March 24th, 2014 at $45.50. In approximately 3 weeks, Claymore/MAC Global Solar Energy Index ETF has returned 11.45% as of today's recent price of $40.29.

'Fast Money' Recap: The Profit-Taking Spreads
at The Street - Tue Apr 08, 4:00AM CDT
The trading panel discussed how investors are selling all sorts of sectors, including steel and home improvement.

These 3 Stocks Are Down 25% in a Month: What Should Investors Do?
Jason Hall, The Motley Fool - Motley Fool - Fri Apr 04, 9:34PM CDT
Energy efficiency, 3-D printing materials, and solar panel experts  Ameresco  ,  ExOne  , and  Trina Solar  have all seen their stocks fall more than 26% during the past four weeks: TSL data by YCharts Besides that, all three are also in...

'Fast Money' Recap: Momentum Shift
at The Street - Fri Apr 04, 4:00AM CDT
The trading panel discussed why the bounce in momentum stocks didn't last longer.

21.5% Return Seen to Date on SmarTrend Claymore/MAC Global Solar Energy Index ETF Call (TAN)
Comtex SmarTrend(R) - Tue Mar 18, 4:52PM CDT
SmarTrend identified an Uptrend for Claymore/MAC Global Solar Energy Index ETF (NYSE:TAN) on February 10th, 2014 at $40.20. In approximately 1 month, Claymore/MAC Global Solar Energy Index ETF has returned 21.51% as of today's recent price of $48.84.

Is Now the Time to Buy Hanwha SolarOne?
Scott Levine, The Motley Fool - Motley Fool - Mon Mar 17, 2:28PM CDT
Source: Hanwha SolarOne Prior to its fourth quarter earnings release, I addressed some promising signs regarding  Hanwha SolarOne   but, in the end, adopted a bearish view on the company. For the fourth quarter, the company posted a GAAP loss of...

3 Green Energy ETF Buys for St Patrick's Day - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Mon Mar 17, 5:01AM CDT
These clean energy ETFs are all buys and could add some green to your portfolio in the near term.

Claymore/MAC Global Solar Energy Index ETF Shares Up 18.4% Since SmarTrend's Buy Recommendation (TAN)
Comtex SmarTrend(R) - Tue Mar 04, 9:44AM CST
SmarTrend identified an Uptrend for Claymore/MAC Global Solar Energy Index ETF (NYSE:TAN) on February 10th, 2014 at $40.20. In approximately 3 weeks, Claymore/MAC Global Solar Energy Index ETF has returned 18.40% as of today's recent price of $47.59.

Best and Worst ETFs of February - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Mon Mar 03, 11:00AM CST
Despite a shaky start, stocks ended February on a positive note.

3 ETFs in Focus on First Solar Q4 Earnings Miss - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 7:01AM CST
With the earnings miss from First Solar (FSLR), these clean energy ETFs could be in focus.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 202

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 199

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 166

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
Clarins Dazzles Austin with Skin Longevity Event

Updated Category News Views 42

Clarins Takes Austin by Storm Under the vast Austin sky, something remarkable unfolded as Clarins transformed the scene with a flashy rooftop affair that screamed innovation and elegance. They weren’t just showing off fancy bottles of beauty potion; they were stirring the pot, merging science with a splash of high-end glitz. This wasn’t just another product pitch—it...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 249

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 309

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 186

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves

Updated Category News Views 84

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 393

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 92

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading

Top 5 Most Recently Viewed Articles

Farmmi Receives Extension to Comply with NASDAQ Requirements

Updated Category News Views 64

Farmmi Secures NASDAQ Compliance Extension Farmmi, Inc. (NASDAQ: FAMI), a supplier of agricultural products, has been granted a 180-day extension by NASDAQ to meet its crucial minimum bid price requirement. This extension allows the company until the spring of 2025 to elevate its ordinary share bid price to at least $1.00 for at least ten consecutive business days. The...

Continue Reading
The Neurotechnology Surge: $57B Market by 2034

Updated Category News Views 16

Neurotechnology: The Rising Giant Elbows on the table, let's chew the fat about neurotechnology. The market, dizzyingly projected to soar past USD 57 billion by 2034, is on an explosive trajectory. Folk wiser than us predict an annual growth rate hanging around 14%. This ain't just whispers in coffee shops; it's cold, hard data from DelveInsight’s Market Insights...

Continue Reading
Reviva Pharmaceuticals' New Phase 3 Study for Schizophrenia Drug

Updated Category News Views 99

Reviva Pharmaceuticals' Regulatory Update Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH) has recently provided an update regarding their journey with brilaroxazine, a novel drug aimed at treating schizophrenia. This news comes after a pre-New Drug Application meeting with the U.S. Food and Drug Administration (FDA). About Brilaroxazine Brilaroxazine is an innovative...

Continue Reading
Lowe's Reports Strong Earnings Amid Strategic Acquisitions

Updated Category News Views 117

Strong Q2 Earnings Surprise Lowe’s Companies Inc (NYSE: LOW) experienced better-than-expected second quarter earnings, bringing a burst of optimism for investors. The home improvement giant saw its stock increase by approximately 2% shortly after announcing its Q2 financial results. Having recorded solid performance through the quarter, Lowe’s exceeded analysts'...

Continue Reading
Invideo and Kling AI Unite for Game-Changing Visuals

Updated Category News Views 153

Invideo and Kling AI Collaborate to Redefine Video Editing Invideo has recently partnered with Kling AI to introduce an exciting tool known as VFX House. This innovative feature empowers creators with studio-level control for their video projects, offering enhanced capabilities for both marketing and editorial work. Unlocking New Possibilities with VFX House The...

Continue Reading